Valo

Valo Networks Chooses Ekinops to Deliver 'Fiber to the Farm'

Retrieved on: 
Monday, April 29, 2024
Valo, School, AB, Euronext Paris, Agriculture, Open Access Network, OTN, Farm, OAN, Digital divide, Architecture, Internet service provider

Valo Networks, launched in 2019, specializes in operating next-generation fiber-optic and wireless networks.

Key Points: 
  • Valo Networks, launched in 2019, specializes in operating next-generation fiber-optic and wireless networks.
  • To serve Canadian communities like Red Deer County, Valo Networks created its Open Access Network (OAN) network architecture that provides scalable, accessible, and future-proof capacity that can be customized for individual communities.
  • Red Deer County contracted Valo Networks to oversee the expansion of broadband Internet services to thousands of rural residents under-served by existing private sector service providers.
  • "The key to our OAN architecture is its openness at all network layers," commented Michael Stelck, Chief Commercial Officer of Valo Networks.

Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

Retrieved on: 
Tuesday, April 16, 2024
Research, Animal Welfare, Medical Devices, Public Policy, Government, Biotechnology, Health, Pharmaceutical, General Health, Science, Corporation, Safety, Policy, Valo, AI, Animal, Pathology, Logica, Patient safety, AMAP, Patient, The three Rs, Multimedia, Non-governmental organization, Drug development, CRL, Drug discovery, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.
  • This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce the use of animal testing.
  • View the full release here: https://www.businesswire.com/news/home/20240416134140/en/
    Understanding that stakeholders across drug development must collaborate to pursue these advances, AMAP is comprised of Charles River experts in animal welfare, science, technology, operations, and advocacy.
  • AMAP focus is on three key pillars:
    Products & Services: Charles River is committed to innovating and expanding its portfolio to include more animal alternatives.

Lisa P. Young Appointed to Valo's Board of Directors

Retrieved on: 
Thursday, January 4, 2024
Valo, Advancement, Culture, Columbus Museum, Philosophy, Audit committee, Ernst & Young, Business administration, TGH, Trustee, MD, Texas Tech University, Health, Textainer Group Holdings, Accounting, Artificial intelligence, Patient, Therapy, Management

BOSTON, Jan. 4, 2024 /PRNewswire/ -- Valo Health, Inc ("Valo"), a technology company focused on utilizing large scale data and artificial intelligence ("AI") driven computation to discover and develop therapeutics, today announced the appointment of Lisa P. Young to its Board of Directors and as the chair of its Audit Committee. Young is a seasoned board member and global business leader with over 36 years of cross-sector, international experience in public accounting and professional services.

Key Points: 
  • Young is a seasoned board member and global business leader with over 36 years of cross-sector, international experience in public accounting and professional services.
  • "I am honored to welcome Lisa to the Valo Board of Directors.
  • "I am thrilled to join Valo Health's board of directors and to chair its audit committee," said Young.
  • Young holds a Bachelor of Business Administration, Cum Laude, in Finance and Accounting from Texas Tech University, and is a certified public accountant.

How the Valo Hyperfoil is playing a leading role in the marine mobility revolution

Retrieved on: 
Wednesday, November 1, 2023
MIT, Element, Water, Stainless steel, Claude-Louis Navier, Coffee, Carbon, Titanium, Engineering, Software, Skyride, Code, Student, Walking, Valo, Algorithm, Noise, Safety, Hydrofoil, Future, Transport, Electric motor

Tech start-up Valo has revealed more details of its revolutionary new personal watercraft, the Valo Hyperfoil.

Key Points: 
  • Tech start-up Valo has revealed more details of its revolutionary new personal watercraft, the Valo Hyperfoil.
  • The Valo Hyperfoil is a two-person, high-performance, all-electric thrill ride that marks the evolution of the jet ski.
  • When combined with the proprietary Skyride active stabilization software, the Valo Hyperfoil represents a double step forward in marine mobility.
  • ?It?s clearly the right time and place for the marine industry to make this move forward toward a new type of marine mobility.?

Valo, a New Christian Dating App, Focuses on Finding a Relationship instead of Casual Dating

Retrieved on: 
Monday, October 9, 2023
Loneliness, Bangladesh Technical Education Board, Fekete, Culture, Psychology, Environment, Hope, Paralysis, Behavior, Structural load, Kinsey Institute, Retail, Hunting, Management, Valo

The dating scene has witnessed a curious phenomenon – individuals gathering matches like tokens of validation, akin to curating a partner "farm."

Key Points: 
  • The dating scene has witnessed a curious phenomenon – individuals gathering matches like tokens of validation, akin to curating a partner "farm."
  • This behavior, although initially appealing, leads to a puzzling contradiction: an abundance of options resulting in indecision and, ironically, loneliness.
  • "We envision a dating experience that encourages thoughtful consideration and genuine interactions," says Kristiina Fekete, spokesperson for Valo Dating App.
  • Valo Dating App is the biggest and fastest-growing Christian dating app in Scandinavia.

Valo Health to Participate in the Jefferies Global Healthcare Conference

Retrieved on: 
Wednesday, May 24, 2023
Valo, Drug discovery, Artificial intelligence, Health, Conference, Cryptocurrency

BOSTON, May 24, 2023 /PRNewswire/ -- Valo Health, Inc. ("Valo") , the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that its founder and CEO, David Berry, will present at the Jefferies Global Healthcare Conference on June 7, 2023, at 2:30-2:55 pm ET in New York.

Key Points: 
  • BOSTON, May 24, 2023 /PRNewswire/ -- Valo Health, Inc. ("Valo") , the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that its founder and CEO, David Berry, will present at the Jefferies Global Healthcare Conference on June 7, 2023, at 2:30-2:55 pm ET in New York.
  • Valo is also hosting 1x1 meetings with investors on June 7.

Valo Health to Participate in Upcoming Conferences and Events

Retrieved on: 
Monday, May 8, 2023
Valo, Inflammation, Drug discovery, Drug development, Artificial intelligence, Future, Health, Infection, Pharmaceutical industry

BOSTON, May 8, 2023 /PRNewswire/ -- Valo Health, Inc. ("Valo") , the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced its participation in the following upcoming investor conferences and events:

Key Points: 
  • BOSTON, May 8, 2023 /PRNewswire/ -- Valo Health, Inc. ("Valo") , the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced its participation in the following upcoming investor conferences and events:
    Plenary Keynote "Expediting the Future's Arrival", May 17, 11:05 am IST
    Piper Sandler Spring Biopharma Symposium, May 17-18
    Valo is hosting 1x1 meetings with investors on Wednesday, May 17.
  • Showcase Moderator: Showcase Four: Inflammation, Infectious Diseases and Other Innovators,
    Panel Speaker: Biotech Track: New Tech in Drug Development, June 1, 9:00 am ET

Rencore Welcomes back Erwin van Hunen as Chief Technology Officer

Retrieved on: 
Wednesday, March 15, 2023
Comment, Heart, VALO-CD, PNP, MVP, MCM, Valo, Microsoft, Management, Rencor apasionado

MUNICH, Germany, March 15, 2023 /PRNewswire-PRWeb/ -- Rencore, the provider of award-winning software for governing cloud collaboration technology, today announced Erwin van Hunen as a member of the leadership team. Re-joining as Chief Technology Officer (CTO), Erwin brings a wealth of business acumen and technical prowess from both his professional and community roles to help drive an agile business strategy throughout the organization.

Key Points: 
  • MUNICH, Germany, March 15, 2023 /PRNewswire-PRWeb/ -- Rencore, the provider of award-winning software for governing cloud collaboration technology, today announced Erwin van Hunen as a member of the leadership team.
  • Re-joining as Chief Technology Officer (CTO), Erwin brings a wealth of business acumen and technical prowess from both his professional and community roles to help drive an agile business strategy throughout the organization.
  • "We are thrilled to welcome Erwin back at Rencore," said Matthias Einig, CEO and Co-founder at Rencore.
  • "I'm extremely excited to be back at Rencore, a company and team that have always been close to my heart," said van Hunen.

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Retrieved on: 
Wednesday, January 11, 2023
Potyvirus, Therapy, CMC, Immunotherapy, A549, Valo, Vaccine, Infection, A549 cell, Patient, Cancer, Doe, CDMO, GMP

HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.

Key Points: 
  • HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.
  • ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform.
  • Exothera brings expertise in adenovector and A549 cells with a deep knowledge of state-of-the-art manufacturing technology and DoE-based development tools.
  • This important work with Exothera will enable us to develop a large-scale manufacturing process for VALO-D102 to support our future clinical development plans and pave the way for future commercial-scale manufacturing.”

Valo Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Westin St. Francis, Valo, Drug discovery, Architecture, Drug development, Health, Conference, Flagship Pioneering, Neurodegeneration, Artificial intelligence, Doctor of Philosophy, Pharmaceutical industry

BOSTON, Jan. 3, 2023 /PRNewswire/ -- Valo Health, Inc. ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9th – 12th.

Key Points: 
  • BOSTON, Jan. 3, 2023 /PRNewswire/ -- Valo Health, Inc. ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9th – 12th.
  • Valo's management, investor relations and business development leadership will be attending and available throughout the conference for meetings.
  • Valo Health, Inc ("Valo") is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence-driven computation.
  • Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, New York, NY, and San Francisco, CA.